Business and Partnering Strategy

Ausio is seeking partners to co-develop and commercialize
AUS-131 for the following indications:

• Vasomotor Symptoms (VMS) – the lead program for AUS-131 is treatment of VMS; this program has advanced to Phase 2 clinical testing
  
  
• Benign Prostatic Hyperplasia (BPH) – AUS-131 has progressed to Phase 2 clinical testing
  
  
• Acne Indications – The rationale for the topical program for AUS-131 is based on the compound’s antioxidant activity, the demonstrated safety in preclinical studies, and clinical safety and efficacy in an antiblemish clinical trial

Osteoporosis, prostate cancer, and neurodegenerative disease licenses will be considered after further clinical development.

Home Contact UsDirections

© 2009 Ausio Pharmaceuticals, LLC